{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:03:52Z","timestamp":1780308232274,"version":"3.54.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virus Genes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11262-026-02236-9","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:21:22Z","timestamp":1776248482000},"page":"393-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution and emergence of the integrase inhibitor 231 insertion resistance mutation in an HIV-2 strain isolated in central Portugal"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1444-4097","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Pereira-Vaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An\u00e1lia","family":"Carmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edtor","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2236_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/pro.2019","volume":"21","author":"Y Tie","year":"2012","unstructured":"Tie Y, Wang YF, Boross PI et al (2012) Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci 21:339\u2013350. https:\/\/doi.org\/10.1002\/pro.2019","journal-title":"Protein Sci"},{"key":"2236_CR2","doi-asserted-by":"publisher","first-page":"14410","DOI":"10.1073\/pnas.222366699","volume":"99","author":"J Ren","year":"2002","unstructured":"Ren J, Bird LE, Chamberlain PP et al (2002) Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A 99:14410\u201314415. https:\/\/doi.org\/10.1073\/pnas.222366699","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2236_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/cid\/ciaa275","volume":"72","author":"D Berzow","year":"2021","unstructured":"Berzow D, Descamps D, Obermeier M et al (2021) Human immunodeficiency virus-2 (HIV-2): a summary of the present standard of care and treatment options for individuals living with HIV-2 in Western Europe. Clin Infect Dis 72:503\u2013509. https:\/\/doi.org\/10.1093\/cid\/ciaa275","journal-title":"Clin Infect Dis"},{"key":"2236_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/cid\/ciaf110","volume":"81","author":"C Charpentier","year":"2025","unstructured":"Charpentier C, Berzow D, Le Hingrat Q et al (2025) HIV-2 EU-supporting standardized HIV-2 drug resistance interpretation: an update. Clin Infect Dis 81:539\u2013542. https:\/\/doi.org\/10.1093\/cid\/ciaf110","journal-title":"Clin Infect Dis"},{"key":"2236_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/0092-8674(91)90297-c","volume":"67","author":"A Engelman","year":"1991","unstructured":"Engelman A, Mizuuchi K, Craigie R (1991) HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211\u20131221. https:\/\/doi.org\/10.1016\/0092-8674(91)90297-c","journal-title":"Cell"},{"key":"2236_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/jac\/dkn335","volume":"62","author":"B Roquebert","year":"2008","unstructured":"Roquebert B, Damond F, Collin G et al (2008) HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 62:914\u2013920. https:\/\/doi.org\/10.1093\/jac\/dkn335","journal-title":"J Antimicrob Chemother"},{"key":"2236_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045372","volume":"7","author":"RA Smith","year":"2012","unstructured":"Smith RA, Raugi DN, Pan C et al (2012) Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS ONE 7:e45372. https:\/\/doi.org\/10.1371\/journal.pone.0045372","journal-title":"PLoS ONE"},{"key":"2236_CR8","doi-asserted-by":"publisher","unstructured":"JJA van Kampen, E van Nood, R Mahmud et al (2024) Novel dolutegravir and lenacapavir resistance patterns in human immunodeficiency virus type 2 infection: a case report. Open Forum Infect Dis. Oxford University Press, NY. https:\/\/doi.org\/10.1093\/ofid\/ofae705","DOI":"10.1093\/ofid\/ofae705"},{"key":"2236_CR9","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1128\/AAC.49.7.2575-2582.2005","volume":"49","author":"MA Winters","year":"2005","unstructured":"Winters MA, Merigan TC (2005) Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob Agents Chemother 49:2575\u20132582. https:\/\/doi.org\/10.1128\/AAC.49.7.2575-2582.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2236_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/cid\/ciy940","volume":"69","author":"Q Le Hingrat","year":"2019","unstructured":"Le Hingrat Q, Collin G, L\u00ea M et al (2019) A new mechanism of resistance of human immunodeficiency virus type 2 to integrase inhibitors: a 5-amino-acid insertion in the integrase C-terminal domain. Clin Infect Dis 69:657\u2013667. https:\/\/doi.org\/10.1093\/cid\/ciy940","journal-title":"Clin Infect Dis"},{"key":"2236_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jac\/dkab387","volume":"77","author":"Q Le Hingrat","year":"2022","unstructured":"Le Hingrat Q, Collin G, Damond F et al (2022) In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions. J Antimicrob Chemother 77:409\u2013412. https:\/\/doi.org\/10.1093\/jac\/dkab387","journal-title":"J Antimicrob Chemother"},{"key":"2236_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/infdis\/jiac037","volume":"226","author":"RA Smith","year":"2022","unstructured":"Smith RA, Wu VH, Song J et al (2022) Spectrum of activity of raltegravir and dolutegravir against novel treatment-associated mutations in HIV-2 integrase: a phenotypic analysis using an expanded panel of site-directed mutants. J Infect Dis 226:497\u2013509. https:\/\/doi.org\/10.1093\/infdis\/jiac037","journal-title":"J Infect Dis"},{"key":"2236_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-98","volume":"7","author":"D Perez Bercoff","year":"2010","unstructured":"Perez Bercoff D, Triqueneaux P, Lambert C et al (2010) Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 7:98. https:\/\/doi.org\/10.1186\/1742-4690-7-98","journal-title":"Retrovirology"},{"key":"2236_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msae263","volume":"41","author":"S Kumar","year":"2024","unstructured":"Kumar S, Stecher G, Suleski M et al (2024) MEGA12: Molecular Evolutionary Genetic Analysis version 12 for adaptive and green computing. Mol Biol Evol 41:msae263. https:\/\/doi.org\/10.1093\/molbev\/msae263","journal-title":"Mol Biol Evol"},{"key":"2236_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092747","volume":"9","author":"J Cavaco-Silva","year":"2014","unstructured":"Cavaco-Silva J, Abecasis A, Miranda AC et al (2014) HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. PLoS ONE 9:e92747. https:\/\/doi.org\/10.1371\/journal.pone.0092747","journal-title":"PLoS ONE"},{"key":"2236_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf336","volume":"12","author":"KS Hensley","year":"2025","unstructured":"Hensley KS, Gruters RA, van Nood E et al (2025) Insights to a cure: unique controller phenotypes in the Rotterdam HIV-2 cohort. Open Forum Infect Dis 12:ofaf336. https:\/\/doi.org\/10.1093\/ofid\/ofaf336","journal-title":"Open Forum Infect Dis"}],"container-title":["Virus Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-026-02236-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11262-026-02236-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11262-026-02236-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:26:55Z","timestamp":1780306015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11262-026-02236-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1007\/s11262-026-02236-9","relation":{},"ISSN":["0920-8569","1572-994X"],"issn-type":[{"value":"0920-8569","type":"print"},{"value":"1572-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Faculty of Medicine of the University of Coimbra (CE-062\/2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}